MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

0.34 -8.11

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.33

Max

0.37

Põhinäitajad
By Trading Economics
Sissetulek	983K -47M
Müük	505K 14M
Kasumimarginaal	-342.329
Töötajad	161
EBITDA	-346K -46M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+1089.19% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	14. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-30M 75M
Eelmine avamishind	8.45
Eelmine sulgemishind	0.34

Uudiste sentiment

By Acuity

82%

18%

328 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. apr 2026, 23:17 UTC

Tulu

Samsung Forecasts Record First-Quarter Operating Profit

6. apr 2026, 23:00 UTC

Kuumad aktsiad

Stocks to Watch: Health Insurers, Mawson, Owlet

6. apr 2026, 22:13 UTC

Suurimad hinnamuutused turgudel

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6. apr 2026, 21:46 UTC

Omandamised, ülevõtmised, äriostud

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6. apr 2026, 17:09 UTC

Suurimad hinnamuutused turgudel

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6. apr 2026, 16:56 UTC

Uudisväärsed sündmused

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6. apr 2026, 14:47 UTC

Suurimad hinnamuutused turgudel

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6. apr 2026, 23:58 UTC

Market Talk

Uudisväärsed sündmused

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6. apr 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6. apr 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6. apr 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6. apr 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6. apr 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6. apr 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6. apr 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. apr 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. apr 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6. apr 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6. apr 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6. apr 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6. apr 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6. apr 2026, 18:36 UTC

Omandamised, ülevõtmised, äriostud

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. apr 2026, 17:59 UTC

Market Talk

Uudisväärsed sündmused

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6. apr 2026, 17:13 UTC

Omandamised, ülevõtmised, äriostud

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. apr 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6. apr 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. apr 2026, 14:59 UTC

Tulu

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

1089.19% tõus

12 kuu keskmine prognoos

Keskmine 4.4 USD 1089.19%

Kõrge 15 USD

Madal 0.3 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

328 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.